

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

> Title of Invention

Compositions and Methods for in vivo Delivery of Polynucleotide-Based Therapeutics

Application Number:

09/839574

Confirmation Number:

1437

First Named Applicant:

Marston Manthorpe

Attorney Docket Number: 1530.0180002

Search string:

(5264618 or 5459127 or 5641665 or 5693622 or 5703055 or 5861397 or 5910488 or 5994317 or 6022874 or 6147055 or 6228844 or 6399588 or 6586409 or 6670332 or 6696424 or 6706694


or 20030032615 or 20030186913 or 20030191082 or 20030203863 or

20040157789).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
	1	5264618	1993-11-23	Felgner et al.			
	2	5459127	1995-10-17	Felgner et al.			
	3	5641665	1997-06-24	Hobart et al.			
	4	5693622	1997-12-02	Wolff et al.			
	5	5703055	1997-12-30	Felgner et al.			
	6	5861397	1999-01-19	Wheeler			
	7	5910488	1999-06-08	Nabel et al.			
	8	5994317	1999-11-30	Wheeler			
	9	6022874	2000-02-08	Wheeler			
	10	6147055	2000-11-14	Hobart et al.			
	11	6228844	2001-05-08	Wolff et al.	B1		
	12	6399588	2002-06-04	Hobart et al.	B1		i
	13	6586409	2003-07-01	Wheeler	B1		
	14	6670332	2003-12-30	Wheeler	B1		
	15	6696424	2004-02-24	Wheeler	B1		



US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
	1	20030032615	2003-02-13	Felgner et al.	A1		
	2	20030186913	2003-10-02	Wolff et al.	A1		
	3	20030191082	2003-10-09	Wheeler	A1		
	4	20030203863	2003-10-30	Hobart et al.	A1		
	5	20040157789	2004-08-12	Geall	A1		

Signature

Examiner Name	Date





Electronic Filing System (EFS) Data **Electronic Patent Application Submission USPTO** Use Only

EFS ID:

68124

Application ID:

Title of Invention:

09839574

Compositions and Methods for

in vivo Delivery of

Polynucleotide-Based

Therapeutics

First Named Inventor:

Marston Manthorpe

Domestic/Foreign Application:

Domestic Application

Filing Date:

2001-04-23

Effective Receipt Date:

2004-09-08

Submission Type:

Information Disclosure

Statement

Filing Type:

Confirmation number:

1437

Attorney Docket Number:

1530.0180002

Total Fees Authorized:

Digital Certificate Holder: cn=Ann E. Summerfield,ou=Registered Attorneys,ou=Patent and

Trademark Office,ou=Department of Commerce,o=U.S. Government,c=US Certificate Message Digest: b29619426578c1c23c94217c6971429e2fbe5af7



TRANSMITTAL

Electronic Version v1.1
Stylesheet Version v1.1.0

Title of Invention

Compositions and Methods for in vivo Delivery of Polynucleotide-Based Therapeutics

Application Number:

09/839574

Date:

2001-04-23

First Named Applicant:

Marston Manthorpe

Confirmation Number:

1437

Attorney Docket Number: 1530.0180002

I hereby certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Submitted by:	Elec. Sign.	Sign. Capacity
Ann Summerfield Registered Number: 47,982	/Ann SUMMERFIELD/	Attorney

APP ID=09839574 Page 1 of 2

SEP 0 8 2004

Documents being submitted

Files

us-ids IDS15300180002suppl5-usidst.xml

> us-ids.dtd us-ids.xsl

Comments

This Sixth Supplemental Information Disclosure Statement is a continuation of Applicants Fifth Supplemental Information Disclosure Statement filed electronically on February 25, 2003 in connection with this application. This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. 1.114. No statement or fee is required. 37 C.F.R. 1.97(b)